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methodology has been published and is publicly avail-
able.3 The standards for ESMO CPGs include a com-
mon template to facilitate a homogeneous presentation,
the selection of recognised multidisciplinary experts as
main authors, a peer review system controlled by the sub-
ject editor and performed by at least 4 ESMO faculty
members, and the inclusion of levels of evidence and
grades of recommendation for all relevant statements.
We acknowledge deficits in the CPG production,
which are related to the intent of publication and the specific
format. For example, we acknowledge that ESMO CPGs
are not currently using tools such as systematic literature
reviews and the reliance on a rather narrative nature of the
review as well as the lack of more “encompassing” analyses
(eg, cost-benefit considerations). This is directly linked to the
scope of ESMO CPGs to provide information for daily clin-
ical use, in a concise format, for the target audience of
(mainly) European medical oncologists. However, ESMO
CPGs must be considered with regard to the presence of a
plethora of high-volume, systematic guidelines, also intended
for health policy decision-making. ESMO CPGs are
intended to complement these other guidelines. Finally, of
the CPGs reviewed, the ESMO CPG had the highest ratio
of high-quality evidence to low-quality evidence. In conclu-
sion, we would like to quote from a previously published ar-
ticle regarding heterogeneity in cancer guidelines4:
We argue that such CPG heterogeneity is not detri-
mental for guideline quality, dissemination and
adoption. A key point is to define clearly what the
guideline intends to do, for whom and in which cir-
cumstances. There are different needs to be met by
CPG in various health systems, societies, among
health professionals, patients and organisational
structures. Provided methodological standards are
adhered to so as to guarantee high-quality, heteroge-
neity in aspects of development, structure, context,
target user and end point definitions may be needed
in order to better meet divergent patient and physi-
cian demands in a kaleidoscopic world.
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Reply to ESMO Guidelines
Committee comment on ‘Critical
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We thank Cervantes and colleagues for their interest in
our recent article,1 in which we sought to evaluate the de-
velopment processes and scientific content of clinical
practice guidelines (CPGs) for the diagnosis and manage-
ment of rectal cancer. The selected CPGs were produced
by major organizations and societies, including the Euro-
pean Society for Medical Oncology (ESMO), which rep-
resent the key authorities on rectal cancer care in North
America and Europe and have the most credibility with
end users of CPGs. We demonstrated wide variation in
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the overall quality of CPG development, use and interpre-
tation of the evidence base, and recommendations around
key processes of care.
The overarching aim of our study was to perform a
contemporary in-depth appraisal of the scientific recom-
mendations presented in the CPGs. The Appraisal of
Guidelines for Research & Evaluation (AGREE II)
instrument facilitated our work by allowing us to objec-
tively rate the quality of the reporting of the guideline
development process and to compare the CPG recom-
mendations across the board. This does not suggest that
the authors completely agree with or endorse the content
of the documents based solely on the AGREE II scores.
AGREE II scores, which varied widely across the CPGs
we evaluated, are dependent on the reporting of the de-
velopment processes in the actual CPG document being
evaluated.
By intent, our appraisal was limited to the most
recently published CPGs from the representative groups.
We obtained the most up-to-date versions of the CPGs
from the organizations’ official Web sites, including
ESMO’s Web page for CPGs in gastrointestinal cancers.2
Although the ESMO home page has a specific tab for
guidelines that is extensively populated, the colon and rec-
tal cancer consensus statement3 referenced above is not
cited on theWeb site. From their description, this appears
to represent a potentially valuable resource, but the
ESMOCPG end user is also not informed about the state-
ment or its contents, and there is no direct way to obtain
the document from the official Web site.
The ESMO CPGs are practical and concise docu-
ments and ESMO has invested substantial effort and time
in this program to improve patient care. As summarized
by our findings,1 there are several strengths to the ESMO
CPGs, including a relatively high percent of references to
randomized controlled trials. We appreciate the attention
shown by Cervantes and colleagues to the importance of
guidelines and believe that they share our goal of develop-
ing high-quality CPGs that synthesize recommendations
based on the best available evidence. Indeed, many of their
points should be shared on the official ESMO Web site
and made a formal component of ESMO’s guideline pro-
gram. Importantly, the document containing the ESMO
policies and procedures for guideline development4 is not
readily identifiable from the appraised CPG document
nor the ESMO Web site, and it should be referenced in
future CPGs and made easily available to end users. This
additional information improves transparency and affords
users of the CPG a critical understanding of how the
guidelines were developed and may result in a higher level
of trust in the recommendations. Easier access to the
appropriate consensus statements would serve the same
purpose.
Finally, although we agree that some heterogeneity
in clinical practice to provide individualized and patient-
centered medicine is necessary and important, heteroge-
neity in guideline development is not necessarily benefi-
cial within the context of evidence-based medical care.
Critically, clinicians must have access to trustworthy
guidelines and recommendations that take the weight of
various sources of data into account. Our study found
that even data from randomized controlled trials are
interpreted differently across groups.1 This further
emphasizes our conclusions that there may not be a com-
prehensive and reliable resource to guide providers in the
delivery of high-quality, guideline-concordant cancer
care.
FUNDING SUPPORT
No specific funding was disclosed.
CONFLICT OF INTEREST DISCLOSURES
Dr. Abdelsattar was supported by grant T32 HS000053-22 from
the Agency for Healthcare Research and Quality and Dr.Wong was
supported by grants from the Agency for Healthcare Research and
Quality (grant 1K08 HS20937-01) and the American Cancer Soci-
ety for work performed as part of the current study.
REFERENCES
1. Abdelsattar ZM, Reames BN, Regenbogen SE, Hendren S, Wong SL.
Critical evaluation of the scientific content in clinical practice guide-
lines [published online ahead of print November 6, 2014]. Cancer.
doi: 10.1002/cncr.29124.
2. European Society for Medical Oncology. ESMO Clinical Practice
Guidelines: Gastrointestinal Cancers. Available at: esmo.org/Guide-
lines/Gastrointestinal-Cancers. Accessed December 29, 2014.
3. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guide-
lines for management of patients with colon and rectal cancer. A per-
sonalized approach to clinical decision making. Ann Oncol. 2012;23:
2479-2516.
4. Pavlidis N, Stahel R, Hansen H, Cervantes A. Fourteen years of evo-
lution of ESMO Guidelines: from the minimum recommendations to
the Consensus Conference-derived guidelines. Ann Oncol. 2011;22
(suppl 6):vi7-vi11.
Zaid M. Abdelsattar, MD
Sandra L. Wong, MD, MS
Center for Healthcare Outcomes & Policy
Department of Surgery
University of Michigan
Ann Arbor, MI
DOI: 10.1002/cncr.29263, Published online January 29, 2015
in Wiley Online Library (wileyonlinelibrary.com)
Correspondence
Cancer June 1, 2015 1909
